Comparative Study of Menstrual Blood and Systemic Blood

December 1, 2022 updated by: Paul D Blumenthal, Stanford University

Comparative Study of Menstrual Blood and Systemic Blood: Quantifying the Difference

The purpose is to investigate how menstrual blood differs from systemic blood to evaluate if menstrual blood could be utilized as a natural and non-invasive access to blood for regular health monitoring and early diagnostics.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Stanford, California, United States, 94305
        • Stanford University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Healthy menstruating women.

Description

Inclusion Criteria:

  • Age 18-45

Exclusion Criteria:

  • weigh less then 110 pounds
  • currently on a birth control method

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health Markers in Systemic Blood vs. Menstrual Blood
Time Frame: Up to 2 months

The following biomarkers will be tested for and then compared for systemic blood and menstrual blood:

  • BUN
  • Sodium
  • Potassium
  • Chloride
  • Glucose
  • Calcium
  • HDL
  • LDL
  • Triglycerides
  • CRP
  • Estradiol
  • Ferritin
  • A1c
  • Hemoglobin
  • Hepatic function panel
  • TSH
  • FSH
  • T3
Up to 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stanford University

Investigators

  • Principal Investigator: Paul D Blumenthal, MD, MPH, Stanford University, Department of OB/GYN

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2016

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

April 7, 2016

First Submitted That Met QC Criteria

April 14, 2016

First Posted (Estimate)

April 15, 2016

Study Record Updates

Last Update Posted (Actual)

December 5, 2022

Last Update Submitted That Met QC Criteria

December 1, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 35817

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Retention; Menstruation

Clinical Trials on Comparative blood analysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe